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Abstract
A major and early feature of cartilage degeneration is
proteoglycan breakdown. Matrix metalloprotease (MMP)-13
plays an important role in cartilage degradation in osteoarthritis
(OA). This MMP, in addition to initiating collagen fibre cleavage,
acts on several proteoglycans. One of the proteoglycan families,
termed small leucine-rich proteoglycans (SLRPs), was found to
be involved in collagen fibril formation/interaction, with some
members playing a role in the OA process. We investigated the
ability of MMP-13 to cleave members of two classes of SLRPs:
biglycan and decorin; and fibromodulin and lumican. SLRPs
were isolated from human normal and OA cartilage using
guanidinium chloride (4 mol/l) extraction. Digestion products
were examined using Western blotting. The identities of the
MMP-13 degradation products of biglycan and decorin (using
specific substrates) were determined following electrophoresis
and microsequencing. We found that the SLRPs studied were
cleaved to differing extents by human MMP-13. Although only
minimal cleavage of decorin and lumican was observed,
cleavage of fibromodulin and biglycan was extensive,
suggesting that both molecules are preferential substrates. In
contrast to biglycan, decorin and lumican, which yielded a
degradation pattern similar for both normal and OA cartilage,
fibromodulin had a higher level of degradation with increased
cartilage damage. Microsequencing revealed a novel major
cleavage site (... G177/V178) for biglycan and a potential cleavage
site for decorin upon exposure to MMP-13. We showed, for the
first time, that MMP-13 can degrade members from two classes
of the SLRP family, and identified the site at which biglycan is
cleaved by MMP-13. MMP-13 induced SLRP degradation may
represent an early critical event, which may in turn affect the
collagen network by exposing the MMP-13 cleavage site in this
macromolecule. Awareness of SLRP degradation products,
especially those of biglycan and fibromodulin, may assist in early
detection of OA cartilage degradation.
Introduction
Osteoarthritis (OA) is the most common rheumatologic dis-
ease, with high incidence and morbidity. Even though the early
pathophysiological process remains to be elucidated, one of
the first alterations in OA cartilage is a decrease in proteogly-
can content [1]. Proteoglycans form a large group that can be
classified into five families according to the structural proper-
ties of their core protein [2]. One group, termed the small leu-
cine-rich proteoglycans (SLRPs), possesses a central domain
of characteristic repeats that participate in protein-protein
interactions [3]. The SLRPs can be divided into four classes
based on gene organization and amino acid sequence homol-
ogies [1]: class I includes decorin, biglycan and asporin; class
II includes fibromodulin, lumican, keratocan, PRELP (proline
arginine-rich end leucine-rich repeat protein) and osteoad-
herin; class III includes epiphycan, mimecan and opticin; and
class IV includes chondroadherin and the recently identified
nyctalopin [4].
Although an understanding of the functions of SLRPs is only
now emerging, most of the members bind specifically to other
extracellular matrix constituents and contribute to the struc-
tural framework of connective tissues [3]. Moreover, some
were shown to interact with various collagen types, including
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collagen type II, and to influence collagen fibril formation and
interaction. These include decorin [5], fibromodulin [6],
asporin [7], lumican [8], PRELP [9] and chondroadherin [10].
Moreover, fibromodulin, asporin, biglycan, decorin and lumi-
can were also suggested to play a role in the OA cartilage
process [11-13].
Decorin was the first in this series of molecules to be structur-
ally defined. It contains one glycosaminoglycan chain, often
dermatan sulfate, which can adopt complex secondary struc-
tures and form specific interactions with matrix molecules [3].
The decorin level in cartilage is by far the most abundant of the
SLRPs, and in humans its level increases with increasing age
[14]. Its proposed major functions are the regulation of colla-
gen fibrillogenesis and maintenance of tissue integrity by its
binding with fibronectin and thrombospondin [15-17] The
closely related family member biglycan, despite its 57% of
homology with decorin [18], does not interact with collagen
under all conditions. Biglycan interactions appear to be prima-
rily with type VI collagen. Biglycan has been identified at the
surface of cartilage and in the pericellular region. In OA carti-
lage, a higher concentration was reported in the deeper layers
of the tissue [19].
Fibromodulin contains up to four keratan sulphate chains [5]
and was originally described as a collagen-binding protein. It
is able to influence collagen fibril formation and maintain a sus-
tained interaction with the formed fibrils [20]. Lumican, which
is present at a high level in the cornea [21], has a widespread
distribution in connective tissues [5,22,23], including cartilage
[24]. Lumican and fibromodulin have been shown to bind to
the same site on the collagen fibril [20,25]. Lumican modu-
lates collagen fibrillogenesis and enhances collagen fibril sta-
bility [26].
Synthesis of collagen in normal and pathological cartilage is
slow. However, in OA the integrity of the collagen network is
impaired. This could result from defective linking of the colla-
gen fibrils by molecules such as the SLRPs, thus interfering
with the network stability, preventing its repair and accelerat-
ing its degradation. Cleavage of the SLRPs may then precede
major destruction of the collagen and contribute to this proc-
ess [20]. Data in the literature show that members of the matrix
metalloprotease (MMP) family are able to cleave some SLRPs.
MT1-MMP can cleave human recombinant lumican [27];
MMP-2, MMP-3 and MMP-7 cleave human recombinant deco-
rin [15]; and MMP-13 cleaves bovine fibromodulin when this
molecule is bound to collagen [20]. Purified bovine fibromod-
ulin cannot be cleaved by human MMP-13 [20]. It was also
recently shown that truncated disintegrin-like and metallopro-
tease domain with thrombospondin type I motifs-4 (ADAMTS-
4) can cleave the MMP-13 susceptible bond of fibromodulin
[28]. However, MMP-2, MMP-8 and MMP-9 do not cleave
fibromodulin [20].
Although various MMPs are present in human OA cartilage,
MMP-13 was demonstrated to play a major role. This enzyme,
in addition to cleaving native collagen and having a higher
activity on type II collagen than MMP-1, also acts to degrade
various extracellular macromolecules including proteoglycans
[29]. However, limited studies have been done on its effect on
the SLRPs. We therefore investigated the ability of human
recombinant MMP-13 to cleave members of two classes of the
SLRPs (class I decorin and biglycan, and class II fibromodulin
and lumican), derived from normal and OA human cartilage dif-
fering in the severity of the disease process. The results show
that MMP-13 can degrade all four SLRPs, with fibromodulin
and biglycan being preferential substrates.
Materials and methods
Specimen selection
Normal human cartilage (femoral condyles and tibial plateaus)
was obtained from individuals within 12 hours of death at time
of autopsy (n = 3; mean age [± standard deviation] 52 ± 14
years). These individuals had no history of joint disease and
died from causes unrelated to arthritic diseases, including car-
diorespiratory arrest, cerebral haemorrhage and pulmonary
embolism. The tissue was examined macroscopically and his-
tologically to ensure that only normal tissue was used.
OA human cartilage (femoral condyles and tibial plateaus) was
obtained from patients undergoing total knee arthroplasty (n =
9; mean age [± standard deviation] 76 ± 5 years). All patients
were evaluated by a certified rheumatologist who used the
American College of Rheumatology criteria for OA of the knee
[30]. These specimens represented early, moderate, or severe
OA, as defined by microscopic criteria [31-33]. The Clinical
Research Ethics Committee of the University of Montreal Hos-
pital Center approved the study protocol and the use of human
tissues.
Proteoglycan extraction
Proteoglycans were extracted with 4 mol/l guanidinium chlo-
ride [34,35]. Briefly, cartilage was finely diced to pieces and
extracted with 4 mol/l guanidinium chloride (Invitrogen Inc.,
Carlsbad, CA, USA) in 0.1 mol/l sodium acetate (pH 6.0) con-
taining protease inhibitors (leupeptin [10 µg/ml], pepstatin [10
µg/ml], aprotinin [10 µg/ml], 1,10-phenanthroline [10 µg/ml]
and phenylmethanesulphonyl fluoride [100 µg/ml]; EMD Bio-
sciences Inc., La Jolla, CA, USA) at 4°C with continuous stir-
ring for 48 hours. The extract was then separated from the
cartilage residue by filtration through glass wool, and then dia-
lyzed for 48 hours against 50 mmol/l Tris buffer (pH 7.5). One
might argue that because the inhibitors were removed during
the dialysis the endogenous MMPs could have been activated.
However, because 1,10-phenanthroline is a zinc chelator, the
catalytic zinc would also be removed by the dialysis, and so
the MMPs would remain inactive.Available online http://arthritis-research.com/content/8/1/R26
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Analysis of SLRP cleavage by MMP-13
MMP-13 proteolytic activity was analyzed on human normal (n
= 3) and OA cartilage having different levels of fibrillation cor-
responding to the different stage of the disease process.
These were named slightly (n = 3), moderately (n = 3) and
severely (n  = 3) fibrillated cartilage. Proteoglycan extracts
were incubated for 0–16 hours with human recombinant
(rh)MMP-13 (R&D Systems Inc., Minneapolis, MN, USA) acti-
vated with 0.5 mmol/l aminophenylmercuric acetate (APMA;
Kodak Inc., Toronto, ON, Canada) in 50 mmol/l Tris-HCl (pH
7.5) containing 10 mmol/l CaCl2 and 0.05% Brij 35 (Sigma-
Aldrich Canada Ltd., Oakville, ON, Canada) at an MMP-13/
proteoglycan ratio of 1:50 (100 ng/5 µg). Glycosaminoglycan
content was determined using the 1,2-dimethylmethylene blue
(DMMB) method [36]. The reaction was stopped by the addi-
tion of EDTA (Sigma-Aldrich Canada Ltd.) at a final concentra-
tion of 15 mmol/l. The samples were treated with 25 mU
chondroitinase ABC (#C-2905; Sigma-Aldrich Canada Ltd.)/
100 µl proteoglycan extract overnight at 37°C. In addition, a
control was performed with the moderately fibrillated cartilage
in which no MMP-13 was added and samples were incubated
for 16 hours. Data were identical to those with the nonincu-
bated specimens (data not shown).
In order to investigate MMP-13 specificity, RS 110–2481 (a
synthetic specific MMP-13 carboxylate inhibitor generously
provided by C Myers [Roche Bioscience, Palo Alto, CA, USA])
[37], was used. The Ki (nmol/l) for MMP-1, MMP-2, MMP-3,
MMP-8 and MMP-13 were 1:100, 32, 19, 18 and 0.08,
respectively. Briefly, samples from moderately fibrillated carti-
lage extract were treated with rhMMP-13 and RS 110–2481
at 1 and 50 nmol/l for the indicated time, and samples proc-
essed for Western blotting.
Western blotting
Proteoglycan solutions were mixed with a sample buffer (62.5
mmol/l Tris-HCl [pH 6.8], 2% w/v sodium dodecyl sulphate,
10% glycerol, 5% β-mercaptoethanol, and 0.05% bromophe-
nol blue) and electrophoresed on 4–20% Ready-Gels (Bio-
Rad Laboratories Ltd., Mississauga, ON, Canada). They were
then transferred electrophoretically to nitrocellulose mem-
branes (Bio-Rad Laboratories Ltd.) and processed for West-
ern immunoblotting. Blots were blocked in 2% low fat dry milk
in Tris-buffered saline containing 0.05% Tween 20 (Sigma-
Aldrich Canada Ltd.). As described previously [11], rabbit pol-
yclonal antibodies raised against synthetic peptides corre-
sponding to the carboxyl-terminus of the SLRP core proteins
were used as primary antibodies for the detection of biglycan
(1/5,000 dilution), fibromodulin (1/10,000 dilution), lumican
(1/5,000 dilution) and decorin (1/5,000 dilution). The second
antibody was a horseradish peroxidase-conjugated goat anti-
rabbit immunoglobulin (1/10,000 dilution; Pierce, Rockford,
IL, USA). Detection was performed by chemiluminescence
using the Super Signal® ULTRA chemiluminescent substrate
(Pierce), in accordance with the manufacturer's specifications.
Sequencing of biglycan and decorin degradation 
products
Bovine recombinant biglycan (15 µg) and decorin (15 µg;
Sigma-Aldrich Canada Ltd.) were incubated for 1 hour at
37°C with APMA-activated rhMMP-13 in 50 mmol/l Tris-HCl
(pH 7.5), containing 10 nmol/l CaCl2 and 0.05% Brij 35. The
reaction was stopped by the addition of EDTA at a final con-
centration of 15 mmol/l. Glycosaminoglycan chains were
removed by incubation with 0.1 unit chondroitinase ABC (#C-
3667; Sigma-Aldrich Canada Ltd.) for 8 hours at room temper-
ature, followed by boiling for 5 minutes with the electrophore-
sis sample buffer. To remove Asn-linked oligosaccharides, N-
glycanase (0.3 unit; Roche Diagnostics, Laval, QC, Canada)
and sample buffer containing 1.2% Nonidet P-40 (Roche
Diagnostics) were added to the solution, which was then incu-
bated again for 12 hours at room temperature. Degradation
products were separated in 4–20% polyacrylamide gels (Bio-
Rad Laboratories Ltd.). After electrophoresis, the gels were
soaked in CAPS transfer buffer (10 nmol/l 3-cyclohexylamino-
1-propanesulfonic acid, 10% methanol; pH 11.0) for 15 min-
utes at 0.25 A. After washing, the proteins were transferred
onto PVDF membranes (Millipore Corporation, Bedford, MA,
USA), which were washed in de-ionized water, stained with
0.1% Coomassie Blue in 50% methanol for 5 minutes, and
then de-stained in 50% methanol and 10% acetic acid for 5–
7 minutes at room temperature. Finally, the membrane was
rinsed in de-ionized water, air dried and stored at room tem-
perature. Amino-terminal amino acid sequencing of the protein
band was performed on a Procise Protein Sequencer model
492 (Applied Biosystems, Foster City, CA, USA).
Results
The use of human cartilage extracts to analyze SLRP degrada-
tion allowed study of all four SLRPs in a single extract under
identical conditions, and permitted SLRP degradation to be
carried out in a physiologically relevant extract of matrix
proteins.
MMP-13 degrades biglycan and decorin
Biglycan in human normal and OA cartilage migrated as a dou-
blet at 48 and 45 kDa, representing intact and amino-termi-
nally processed biglycan. MMP-13 degradation of biglycan
was detected at 0.25 hours of incubation, and was almost
complete at 2 hours (Figure 1). A fragment of about 28 kDa
was generated. The biglycan profile from normal (nonfibril-
lated) to moderately fibrillated (Figure 1a–c) cartilage was sim-
ilar whether the specimens were incubated in the presence or
absence of MMP-13. Of note, in the specimens from nonfibril-
lated to moderately fibrillated cartilage not treated with MMP-
13, a biglycan degradation product of a similar size to that
generated by MMP-13 was already present, although in low
amounts. Under MMP-13 treatment, there was an increase of
the degradation product until complete digestion of the sub-
strate. Interestingly, but not unexpectedly, in the severely fibril-
lated cartilage the biglycan was in low abundance (Figure 1d),Arthritis Research & Therapy    Vol 8 No 1    Monfort et al.
Page 4 of 9
(page number not for citation purposes)
which was possibly due to prior degradation and loss from the
tissue. However, MMP-13 further cleaved the residual
substrate.
To determine whether MMP-13 was the sole enzyme respon-
sible for the cleavage, and not other enzymes present in the
cartilage extracts, we further treated the samples from the
moderately fibrillated cartilage with two concentrations (1 and
50 nmol/l) of a preferential inhibitor of MMP-13, namely RS
110–2481 [37]. Biglycan degradation was completely pre-
vented at both concentrations tested (Figure 1e).
Decorin from normal and OA cartilage migrated as a single
band of about 45 kDa. MMP-13 degradation of decorin was
not detected until 4–8 hours of incubation, and proteolysis
was complete by 16 hours (Figure 2). Two decorin fragments
of about 30 and 28 kDa were detected. There was no major
difference in the degradation pattern with the normal to mod-
erately fibrillated cartilage (Figure 2a–c). In the severely fibril-
lated cartilage, no decorin fragment could be seen (Figure 2d).
The ability of MMP-13 to degrade decorin was prevented in
the presence of RS 110–2481 when the moderately fibrillated
cartilage was incubated for 16 hours, but only at the higher
concentration tested (50 nmol/l; Figure 2e). Of note, as deco-
rin fragmentation was seen at early incubation time, this exper-
iment was also performed at 1.5 hours and the data were
identical (for instance, degradation was completely prevented
at 50 nmol/l; data not shown).
MMP-13 cleavage sites of biglycan and decorin
Amino acid sequencing analysis was performed with recom-
binant biglycan and decorin treated with MMP-13. In contrast
to the Western blotting, which identifies carboxyl-terminal
fragments, sequence analysis can identify the amino-terminus
of all fragments.
Sequence analysis of the biglycan fragments generated by
MMP-13 treatment revealed a novel major fragment of 28 kDa.
This fragment is generated by cleavage between positions
177 and 178 of the mature biglycan core protein, thus
between glycine (G) and valine (V; Figure 3). A second bigly-
can fragment of 22 kDa was also identified by blotting and
therefore possessed the carboxyl-terminal sequence. Presum-
ably, this fragment is derived by cleavage within the 28 kDa
fragment (Figure 3).
Sequence analysis of the two decorin cleavage fragments of
28 and 26 kDa showed that they possessed the same amino-
terminus. The larger fragment is compatible with cleavage
between positions 240 and 241 of the peptidic chain corre-
sponding to a previously reported [15] cleavage site between
the serine (S) and leucine (L). The exact cleavage site of the
smaller fragment could not be identified.
The SLRP fragment sizes visualized on the gel used for
sequencing were smaller than those observed on the gel used
for Western blotting, possibly due to the treatment with N-gly-
Figure 1
Representative Western blot of time course of MMP-13-induced degradation of biglycan Representative Western blot of time course of MMP-13-induced degradation of biglycan. Human articular cartilage extracts were incubated with 
APMA-activated MMP-13 for the indicated times (0–16 hours). Panels are for extracts from (a) normal (nonfibrillated) cartilage and from (b) slightly, 
(c) moderately and (d) severely fibrillated OA cartilage. The bottom panel (e) relates to the extract from moderately fibrillated OA cartilage incubated 
for 1.5 hours with APMA-activated MMP-13 in the absence or presence of 50 or 1 nmol/l RS 110–2481 (a preferential MMP-13 inhibitor). APMA, 
aminophenylmercuric acetate; MMP, matrix metalloprotease; OA, osteoarthritis; rh, human recombinant.Available online http://arthritis-research.com/content/8/1/R26
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canase in the former procedure. Of note, molecular weight
determination by Western blotting is an approximation.
Degradation of fibromodulin and lumican
Fibromodulin from normal and OA cartilage migrated as a sin-
gle component of about 60 kDa. MMP-13 induces fibromodu-
lin degradation in a time-dependent manner, being detectable
after 1–2 hours of incubation and complete by 16 hours (Fig-
ure 4). In the moderately and severely fibrillated cartilage, a
degradation product of about 33 kDa was generated early
under MMP-13 treatment (Figure 4c,d). The fragment initially
increased in abundance with incubation time, and thereafter
declined as the fibromodulin was further degraded. The spe-
cific MMP-13 inhibitor prevented fibromodulin degradation
(Figure 4e).
Lumican also migrated as a single component of 60 kDa.
MMP-13-induced degradation was detected only after 8–16
hours of incubation (Figure 5). As for the other SLRPs, the
specificity of MMP-13 was verified on extracts from moder-
ately fibrillated OA cartilage, where lumican degradation was
prevented by treatment with the MMP-13 specific inhibitor
with a greater effect at 50 nmol/l (Figure 5e).
Discussion
A major and early feature of cartilage degeneration is prote-
oglycan breakdown. MMP-13 has been shown to play an
important role in OA cartilage degeneration by its effect not
only on the collagen network but also on proteoglycans [2]. In
the present study we investigated the ability of human MMP-
13 to act on members of the SLRP proteoglycan family
derived from human cartilage ranging from normal to advanced
OA.
Figure 2
Representative Western blot of time course of MMP-13-induced degradation of decorin Representative Western blot of time course of MMP-13-induced degradation of decorin. Human articular cartilage extracts were incubated with 
APMA-activated MMP-13 for the indicated times (0–16 hours). Panels are for extracts from (a) normal (nonfibrillated) cartilage and from (b) slightly, 
(c) moderately and (d) severely fibrillated OA cartilage. The bottom panel (e) relates to the extract from moderately fibrillated OA cartilage incubated 
for 16 hours with APMA-activated MMP-13 in the absence or presence of 50 or 1 nmol/l RS 110–2481 (a preferential MMP-13 inhibitor). APMA, 
aminophenylmercuric acetate; MMP, matrix metalloprotease; OA, osteoarthritis; rh, human recombinant.
Figure 3
Biglycan cleavage sites generated by APMA-activated MMP-13 Biglycan cleavage sites generated by APMA-activated MMP-13. The 
arrow indicates the MMP-13 cleavage site, and the broken arrow the 
potential secondary MMP-13 cleavage site. APMA, aminophenylmercu-
ric acetate; MMP, matrix metalloprotease; G, glycine; V, valine.Arthritis Research & Therapy    Vol 8 No 1    Monfort et al.
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One emerging observation is that biglycan and fibromodulin
are preferential substrates for MMP-13, whereas degradation
of decorin and lumican is much less effective. This could imply
that biglycan and fibromodulin are sensitive to both the gelati-
nolytic and collagenolytic activities of MMP-13, whereas deco-
rin and lumican are more responsive to the gelatinolytic
cleavage. Support for this hypothesis was provided by Imai
and colleagues [15], who showed that decorin could be
cleaved by MMP-2, MMP-3 and MMP-7, whereas cleavage
with MMP-1 was negligible. The greater effect of MMP-13
than of MMP-1 on decorin could be due to the fact that the
former enzyme has 44 times more gelatinolytic activity than
does MMP-1 [38]. Moreover, and in agreement with this
hypothesis, only 1 nmol/l of the inhibitor RS 110–2481 is suf-
ficient to prevent collagenolytic activity, but 50 nmol/l is
required to prevent gelatinolytic activity [37], and the effect of
MMP-13 on biglycan and fibromodulin is abolished at both
inhibitor concentrations whereas the effect on decorin and
lumican is abolished only at the higher concentration.
Biglycan is found in the pericellular matrix of many connective
tissues, and appears to play a role in regulating morphogene-
sis and differentiation [39]. Although biglycan is present in car-
tilage and is upregulated in the late stages of OA [13], its exact
role in OA remains to be determined. The present data show
that in some specimens a biglycan fragment of a similar size to
that generated by MMP-13 is present in the cartilage as a
minor component. It is possible that this in situ degradation
product might not be cleaved at exactly the same site. This
requires further study with an antibody recognizing the amino-
terminal sequence of the fragment; however, such an antibody
is not yet available. It is also possible that the biglycan degra-
dation product may not be stably retained within the cartilage
matrix and hence may not accumulate in large amounts. The
study showed that the degree of biglycan degradation was
independent of the extent of cartilage damage, although the
amount of biglycan present in the severely fibrillated cartilage
was significantly less than in normal to moderately fibrillated
specimens. This suggests that, in the severely fibrillated spec-
imens, biglycan has already been extensively degraded, lead-
ing to the loss of the epitope recognized by the antibody.
Although we cannot exclude the possibility that proteases
other than MMP-13 exerted an affect on this SLRP, this is
unlikely because all endogenous carboxy, serine and MMPs
should have been irreversibly inhibited by the inhibitor cocktail
used in the extraction procedure. Although some cysteine pro-
teases may survive the extraction procedure, it is unlikely that
they remain active at pH 7.5, which was used for the
incubation.
Our data also showed that MMP-13 induces two main bigly-
can fragments. The larger fragment possessed a new
Figure 4
Time course of MMP-13 induced degradation of fibromodulin Time course of MMP-13 induced degradation of fibromodulin. Human articular cartilage extracts were incubated with APMA-activated MMP-13 for 
the indicated times (0–16 hours). Panels are for extracts from (a) normal (nonfibrillated) cartilage and from (b) slightly, (c) moderately and (d) 
severely fibrillated OA cartilage. The bottom panel (e) relates to the extract from moderately fibrillated OA cartilage incubated for 1.5 hours with 
APMA-activated MMP-13 in the absence or presence of 50 or 1 nmol/l RS 110–2481 (a preferential MMP-13 inhibitor). APMA, aminophenylmercu-
ric acetate; MMP, matrix metalloprotease; OA, osteoarthritis; rh, human recombinant.Available online http://arthritis-research.com/content/8/1/R26
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cleavage site (... G177-V178) in the leucine-rich region. The sec-
ond smaller fragment possessed the same carboxyl-terminal
sequence, indicating the presence of a second cleavage site.
As the antibody used for immunodetection recognizes the car-
boxyl-terminal region of biglycan, cleavage at this second site
must be after the G177-V178 cleavage site found in the larger
fragment.
As mentioned above, Imai and colleagues [15] demonstrated
the ability of three MMPs – namely MMP-2, MMP-3 and MMP-
7 – to degrade decorin, and reported multiple cleavage sites.
It seems likely that these MMPs cleaved within the leucine-rich
region at different sites, because all fragments, albeit of differ-
ent sizes, possessed the same amino-terminal sequence cor-
responding to that of the intact decorin core protein [15]. The
present study revealed that MMP-13 degrades decorin into
two fragments that also possess the same amino-terminal
sequence as the intact decorin core protein. The products
identified by amino acid sequencing from recombinant decorin
were of 28 and 26 kDa. These may represent the amino-termi-
nal fragments corresponding to the cartilage extract decorin
fragments identified with a carboxyl-terminal antibody,
because it appears that decorin cleavage occurs toward the
centre of the molecule. One would expect the amino-terminal
and carboxyl-terminal fragments to be of similar size. Because
the degradation of decorin by MMP-13 appears to be due to
its gelatinase activity rather than its collagenase activity, it is
likely that one of the MMP-13 cleavages could be at the S240-
L241 site, which is the cleavage used by gelatinase A (MMP-2)
[15], and the other fragment would then be due to a cleavage
amino-terminal of this site. This S240-L241 cleavage site is very
plausible for MMP-13, because it is between aliphatic and
hydrophobic amino acids, which are preferred by MMPs [40].
Interestingly, one of the characteristics of decorin is its inter-
action with active transforming growth factor (TGF)-β, thereby
providing a tissue reservoir of this factor [41]. Our data show-
ing MMP-13 cleavage in the leucine-rich repeats suggests the
possibility that TGF-β may be released from the decorin after
digestion with this MMP. We recently reported that, in OA car-
tilage, the TGF-β level is upregulated and responsible for the
in situ increase in MMP-13 in this disease tissue [42,43]. The
effect of MMP-13 on decorin, although not a preferential sub-
strate, could be threefold. It may permit collagen degradation
by its loss from the surface of the collagen fibrils; since data
suggest that the leucine-rich repeats play a critical role in the
interaction of SLRPs with collagens [44], it may result in loss
of tissue integrity through the functional failure of decorin and
biglycan interactions; and it may promote tissue degradation
via TGF-β release, leading to increased MMP-13 production.
Figure 5
Time course of MMP-13 induced -degradation of lumican Time course of MMP-13 induced -degradation of lumican. Human articular cartilage extracts were incubated with APMA-activated MMP-13 for the 
indicated times (0–16 hours). Panels are for extracts from (a) normal (nonfibrillated) cartilage and from (b) slightly, (c) moderately and (d) severely 
fibrillated OA cartilage. The bottom panel (e) relates to the extract from moderately fibrillated OA cartilage incubated for 16 hours with APMA-acti-
vated MMP-13 in the absence or presence of 50 or 1 nmol/l RS 110–2481 (a preferential MMP-13 inhibitor). APMA, aminophenylmercuric acetate; 
MMP, matrix metalloprotease; OA, osteoarthritis; rh, human recombinant.Arthritis Research & Therapy    Vol 8 No 1    Monfort et al.
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Lumican was reported to be present in human cartilage [24],
but no direct evidence of its involvement in human OA has yet
been reported. However, Young and colleagues [11] recently
showed that lumican is upregulated in an ovine meniscectomy
model of OA. This upregulated expression in degenerative car-
tilage was associated with increased lumican core protein
deficient in keratan sulphate chains [11]. The present study
showed that lumican degradation by MMP-13 occurs after an
incubation period of 16 hours. This appeared independent of
the level of fibrillation of the cartilage from which it was
extracted, indicating that lumican degradation is independent
of interactions with the various components in the different
cartilage extracts.
Fibromodulin cleavage by MMP-13 has previously been dem-
onstrated [20]. In human fibromodulin, cleavage occurs at the
Y63-T64 site in the amino-terminal region of the molecule. In the
present study MMP-13 degradation of fibromodulin generated
a fragment of 30 kDa, which presumably corresponds to the
fragment described by Heathfield and colleagues [20]. Of
note, this fragment is generated in moderately and severely
fibrillated cartilage, but not in normal or slightly fibrillated carti-
lage, reflecting an increased sensitivity of fibromodulin to deg-
radation when the cartilage is more degenerated. This could
be related to the presence of other components in the carti-
lage extracts that interact with the fibromodulin. Varying abun-
dance of such components between the differently affected
cartilages could then influence MMP-13 cleavage. The work
by Heathfield and colleagues [20] suggests that cleavage of
fibromodulin is dependent on its ability to bind type II collagen.
There are two possibilities that could explain this situation.
First, the ability of isolated SLRPs to interact with one another
could result in the cleavage site being hidden. The recent
description of decorin adopting a dimeric conformation in both
the solution and crystal state may relate to this hypothesis, if
other SLRPs behave in a similar manner [45]. It is possible that
this dimeric conformation is removed when the SLRP binds to
collagen and the MMP-13 cleavage site is then exposed. A
second hypothesis could be that isolated SLRPs can act as
zinc-binding proteins [46]. If this is a property of only free
SLRPs, then in the absence of collagen or other binding part-
ner the molecules could remove the zinc site necessary for
MMP-13 function.
Although MMP-13 was shown to degrade type II collagen
fibrils efficiently [47], it is possible that in vivo SLRP interac-
tion may help to protect the fibrils by impeding access to the
collagenase cleavage site. Data from this study are of impor-
tance in human OA pathophysiology, because MMP-13-
induced SLRP degradation may represent an initial event in
collagen fibril degradation, by exposing the collagen fibrils to
proteolytic attack and permitting subsequent cartilage degen-
eration. In vivo identification of the SLRP degradation prod-
ucts, especially those of biglycan and fibromodulin, may assist
in early detection of degeneration in OA cartilage.
Conclusion
In this study we demonstrated the ability of human recom-
binant MMP-13 to cleave members of two classes of SLRPs
(decorin, biglycan, fibromodulin and lumican) derived from nor-
mal and OA human cartilage differing in severity of the disease
process. Although minimal cleavage of decorin and lumican
was observed, cleavage of fibromodulin and biglycan was
extensive, suggesting that both molecules are preferential
substrates. We demonstrated that fibromodulin has a higher
level of degradation with increased cartilage damage. We also
characterized a novel major cleavage site for biglycan. We
hypothesized that MMP-13-induced SLRP degradation may
represent an early critical event in the process of cartilage deg-
radation. Awareness of the SLRP degradation products may
assist in early detection of OA cartilage degradation.
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